{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-331381","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-08-04T10:01:39+00:00","discovered_at":"2026-08-04T10:10:02.144339+00:00","generated_at":"2026-08-04T10:10:37.426780+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IDEAYA: darovasertib combo meets primary endpoint in mUM; Q2 net loss $112.5M; cash $1.24B","bullets":["Registrational OptimUM-02 trial met primary endpoint: median PFS 6.9 vs 3.1 months (HR 0.42, p<0.0001); NDA filing underway under RTOR.","Q2 2026 net loss $112.5M vs $98.5M in Q1; R&D expenses $108.7M; G&A $22.5M.","Cash, cash equivalents and marketable securities $1.24B as of June 30, 2026; cash runway into 2030 unchanged.","Clinical collaboration with Roche to evaluate IDE892 + RG6505 in MTAP-deleted, RAS-mutant PDAC; Phase 1 combo trial to start H2 2026.","Updated data from IDE849 (DLL3 ADC) and OptimUM-01/09 at ESMO; Phase 3 registrational trial for IDE849 targeted by end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-331381","json":"https://secwatch.observer/filing/0001193125-26-331381.json","markdown":"https://secwatch.observer/filing/0001193125-26-331381.md","text":"https://secwatch.observer/filing/0001193125-26-331381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/0001193125-26-331381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T10:10:37.426780+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}